# Safety and Pharmacokinetics of ODM-208 in Patients With Metastatic Castration-resistant Prostate Cancer

Source: https://onco.cc/trials/nct03436485/  
OnCo record `nct03436485` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Opevesostat in prostate cancer, run by Orion Corporation, Orion Pharma, active and no longer recruiting.

## Summary

Safety and Pharmacokinetics of ODM-208 in Patients With Metastatic Castration-resistant Prostate Cancer is a phase 1/2 interventional study registered as NCT03436485 by Orion Corporation, Orion Pharma, with 204 participants enrolled, started 2018-03-19 and due to reach its primary completion in 2026-10-31. Interventions recorded: ODM-208, Midazolam. Conditions listed: Prostate Cancer Metastatic. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT03436485
- Phase: 1/2
- Setting: Safety and Pharmacokinetics of ODM-208 in Patients With Metastatic Castration-resistant Prostate Cancer
- Sponsor: Orion Corporation, Orion Pharma
- Enrolled: 204

## Sources

- ClinicalTrials.gov NCT03436485: https://clinicaltrials.gov/study/NCT03436485

## Connected records

- cancers: [Prostate cancer](https://onco.cc/cancers/prostate/)
- drugs: [Opevesostat](https://onco.cc/drugs/opevesostat/)
- companies: [Orion, Orion Pharma](https://onco.cc/companies/orion-orion-pharma/)

---
JSON: https://onco.cc/api/v1/entities/nct03436485.json